At BioLab, we believe the best way
to optimize the standard of wound care
is through science, compassion,
and collaboration.
At BioLab, we do not just lead in diagnostics. Through strategic relationships with innovative companies, we help bring cutting-edge medical solutions to market with precision and impact. Our integrated approach ensures that our partners benefit from a seamless go-to-market experience, supported by a trusted network, deep industry insight, and a shared commitment to advancing patient care.
We are always seeking new opportunities to collaborate with forward-thinking organizations that align with our values and vision. Whether it is breakthrough biotech, novel therapeutics or next-generation healthcare tools, we are committed to fostering partnerships that make a meaningful difference in people’s lives.
Why BioLab?
We place the patients in the forefront of our minds. It is imperative that our clients, providers and distributors are able to easily work with us to ensure proper care to the patients treated. We cultivate an environment that creates a beneficial system for the payors, patients and providers.
About Our Team
PR & News
9/4/25
BioLab Holdings, Inc. Announces Strategic Investment in AI Diagnostic Technology
BioLab Holdings, Inc is proud to announce its strategic investment and commercialization partnership with cureVision, a breakthrough digital wound care company using optical sensors, 3D imaging and artificial intelligence, to revolutionize wound analysis and diagnosis.
7/31/25
BioLab Holdings, Inc. Launches Its Largest Clinical Trial to Date Evaluating Human Placental Membrane Products
Study Will Compare Four Amnion-Based Therapies Plus Standard of Care to Standard of Care Alone in Chronic Wound Management
7/22/25
BioLab Holdings, Inc. Launches Multicenter Clinical Trial to Evaluate Amnion Grafts for Chronic Wounds
Study Will Assess Real-World Effectiveness of Tri-Layer and Single-Layer Amnion Grafts in Treating Diabetic Foot and Venous Leg Ulcers
6/6/25
BioLab keeps data room open for potential buyers as it pursues M&A
BioLab, a manufacturer of regenerative wound-care products, is fielding increasing inbound sale interest as it shops globally for potential buys, said CEO Jaime Leija.
3.25.25
BioLab Holdings, Inc. Announces Medical Advisory Board
Distinguished Wound Care Specialists to Provide Invaluable Insights Across BioLab's Operation
3.07.25
BioLab Holdings, Inc. Announces Partnership with Real Collagen GmbH
Investment and Partnership will Allow Manufacturer to Create New Wound Care Products Using Fish Collagen
01.06.25
BioLab Holdings, Inc. Completes Animal Study on New Wound Care Product
Product Shows Promising Long-Term Results in New Study
2.12.25
BioLab Holdings, Inc. Receives IRB Approval for Trial on Membrane Wrap™
Study will Evaluate Efficacy of Skin Substitute on Venous Leg Ulcers
PERFORMANCE
COLLABORATION
INTEGRITY
CARE
IMPACT
INGENUITY
Our Origin Story
Founded in 2018, BioLab Holdings was born from a deep commitment to redefine what it means to care for patients; not just those suffering from chronic wounds, but all individuals across the entire continuum of care. From the very beginning, our company has focused on a “patient-first” philosophy, with a clear mission to elevate the standard of care in wound management and beyond.
At the core of BioLab is a culture of humble leadership and people-first values. The company operates on six guiding principles: performance, collaboration, ingenuity, integrity, care, and impact. These values are reflected in every partnership, product, and innovation, fueling its exponential growth and unwavering focus on its vision since inception.
With a team dedicated to advancing care through science and empathy, BioLab Holdings continues to lead the way in creating meaningful change. Supporting patients at every step and helping clinicians deliver truly life-enhancing outcomes.
- Bob Maguire & Jaime Leija
Co-Founders of Biolab
Our Origin Story
“Before co-founding BioLab Holdings I had a long and successful career in the telecommunications industry. At the age of 50, I decided to return to school to get my executive MBA to sharpen my skills and fill any knowledge gaps I had. It proved very impactful, as it allowed me to see other people at different stages in their careers, and what some of them were achieving or not achieving. It made me reflect internally on what I was doing and how I was using my skills.
On my last day of grad school, I had a life-altering moment — a rollover car accident from which I miraculously walked away without a scratch. The next day I was on a plane to Rochester, New York to start a new position and could not help but wonder, “Am I really doing anything to help improve lives or to help others?”. And the answer, painfully, was no. I was helping businesses become more efficient, but I really was not changing lives.
I wanted to create value for other human beings. So, I made a career shift from software sales to regenerative medicine. Yes, it was a big transition, but we are so fortunate today to have a wealth of information at our fingertips. You truly can learn to do anything new you want.
It is been a great journey to where I am now. Regenerative medicine has come a long way in five years, and I think it is going to keep progressing tremendously as we learn more about how the body can help heal itself. This path is enabling me to help people who are suffering from hard-to-heal wounds. We are helping save people’s limbs. We are absolutely changing lives and improving the quality of it for countless individuals. For me, this line of work definitely feels much better than saving a company money or helping a company achieve a better business plan."
Bob Maguire
Chairman of the Board
Our Executive Team
Jaime Leija
President, Chief Executive Officer and Co-Founder
Carlos Encinas, PhD
Chief Science Officer
Scott Swonger
Chief Financial Officer
Marshall Medley DO, FACOS, CWS-P
Chief Medical Officer
Marty Kuser
Chief Commercialization Officer
Hernan Lopez
Chief Operations Officer
Dixon Terry
Chief Compliance Officer
Deanna Montrose
Chief Innovation Officer
Klint Price
Chief Technology Officer
Chris Silvers
Vice President of Quality Assurance
Alison Nielson
Vice President of Human Resources
Our Advisory Board
Bob Maguire
Chairman of the Board
Jaime Leija
President, Chief Executive Officer and Co-Founder
Carlos Encinas, PhD
Chief Science Officer
Rodrigo Soto, PhD
Plastic Surgeon
Scott Swonger
Chief Financial Officer